Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...

This action follows a recent strategic review of Tetris Pharma, including analysis of the future commercial opportunity for the business's lead product, the ready to-use glucagon auto-injector pen ...

adding that it had mutually agreed with Xeris BioPharma to return the rights to Ogluo - a ready-to-use glucagon auto-injector for severe hypoglycemia. The AIM-traded firm said the decision ...

The move comes alongside a mutual decision with Xeris BioPharma Holdings, Inc. (Nasdaq: XERS) to return the commercial rights to Ogluo®, a glucagon auto-injector pen for severe hypoglycemia. The ...